ProfileGDS5678 / 1424226_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 69% 70% 69% 69% 71% 69% 69% 70% 69% 69% 69% 71% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3544970
GSM967853U87-EV human glioblastoma xenograft - Control 24.2713469
GSM967854U87-EV human glioblastoma xenograft - Control 34.3234270
GSM967855U87-EV human glioblastoma xenograft - Control 44.2821569
GSM967856U87-EV human glioblastoma xenograft - Control 54.2876769
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3830671
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3175569
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2979869
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3524770
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3129169
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2485669
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2906369
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5052171
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3151870